ARIAD Pharma (ARIA) Tops Q2 EPS Views

ARIAD Pharma (NASDAQ: ARIA) reported Q2 EPS of $0.59, $0.70 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.64 million.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• McDonald’s tops EPS estimates, but revenue falls short
• Fidelity National Information Services, Inc. (FIS) Tops Q2 EPS by 1c ; Offers Guidance
• Angel Oak Mortgage (AOMR) Misses Q2 EPS by 19c